162 related articles for article (PubMed ID: 16505706)
1. Clinical correlation with the PA/plasmin system in septic arthritis of the knee.
Hsieh YS; Yang SF; Lue KH; Lu KH
Clin Orthop Relat Res; 2006 Jun; 447():172-8. PubMed ID: 16505706
[TBL] [Abstract][Full Text] [Related]
2. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.
Chu SC; Yang SF; Lue KH; Hsieh YS; Hsiao TY; Lu KH
J Rheumatol; 2006 Feb; 33(2):311-7. PubMed ID: 16465663
[TBL] [Abstract][Full Text] [Related]
3. [Levels of matrix metalloproteinase-3 and urokinase-type plasminogen activator in knee synovial fluids from patients with rheumatoid arthritis and osteoarthritis].
Gotoh H; Yamada H; Yoshihara Y; Kikuchi T; Obata K; Shinmei M
Ryumachi; 1997 Feb; 37(1):3-8. PubMed ID: 9128417
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of gelatinases in septic arthritis of native and replaced knees.
Chu SC; Yang SF; Lue KH; Hsieh YS; Lin ZI; Lu KH
Clin Orthop Relat Res; 2004 Oct; (427):179-83. PubMed ID: 15552155
[TBL] [Abstract][Full Text] [Related]
5. Expression levels of matrix metalloproteinase (MMP)-9 and its specific inhibitor TIMP-1, in septic and aseptic arthritis of the knee.
Fotopoulos VC; Tzinia A; Tzurbakis M; Kalfakakou V; Levidiotou-Stefanou S; Georgoulis A
Knee Surg Sports Traumatol Arthrosc; 2012 Jun; 20(6):1159-67. PubMed ID: 21946941
[TBL] [Abstract][Full Text] [Related]
6. Activated gelatinase-B (MMP-9) and urokinase-type plasminogen activator in synovial fluids of patients with arthritis. Correlation with clinical and experimental variables of inflammation.
Koolwijk P; Miltenburg AM; van Erck MG; Oudshoorn M; Niedbala MJ; Breedveld FC; van Hinsbergh VW
J Rheumatol; 1995 Mar; 22(3):385-93. PubMed ID: 7783051
[TBL] [Abstract][Full Text] [Related]
7. Effects of nonsteroidal anti-inflammatory drugs on the expression of urokinase plasminogen activator and inhibitor and gelatinases in the early osteoarthritic knee of humans.
Yang SF; Hsieh YS; Lue KH; Chu SC; Chang IC; Lu KH
Clin Biochem; 2008 Jan; 41(1-2):109-16. PubMed ID: 17996201
[TBL] [Abstract][Full Text] [Related]
8. Determination of metalloproteinases, plasminogen-activators and their inhibitors in the synovial fluids of patients with rheumatoid arthritis during chemical synoviorthesis.
Blaser J; Triebel S; Maasjosthusmann U; Romisch J; Krahl-Mateblowski U; Freudenberg W; Fricke R; Tschesche H
Clin Chim Acta; 1996 Jan; 244(1):17-33. PubMed ID: 8919199
[TBL] [Abstract][Full Text] [Related]
9. Effects of different molecular weight hyaluronan products on the expression of urokinase plasminogen activator and inhibitor and gelatinases during the early stage of osteoarthritis.
Hsieh YS; Yang SF; Lue KH; Chu SC; Lu KH
J Orthop Res; 2008 Apr; 26(4):475-84. PubMed ID: 17975844
[TBL] [Abstract][Full Text] [Related]
10. Elevations in synovial fluid plasminogen activator in patients with rheumatoid arthritis.
Mochan E; Uhl J
J Rheumatol; 1984 Apr; 11(2):123-8. PubMed ID: 6427461
[TBL] [Abstract][Full Text] [Related]
11. Post-traumatic plasminogenesis in intraarticular exudate in the knee joint.
Rość D; Powierza W; Zastawna E; Drewniak W; Michalski A; Kotschy M
Med Sci Monit; 2002 May; 8(5):CR371-8. PubMed ID: 12011780
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees.
Belcher C; Fawthrop F; Bunning R; Doherty M
Ann Rheum Dis; 1996 Apr; 55(4):230-6. PubMed ID: 8733439
[TBL] [Abstract][Full Text] [Related]
13. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation.
Brommer EJ; Dooijewaard G; Dijkmans BA; Breedveld FC
Thromb Haemost; 1992 Aug; 68(2):180-4. PubMed ID: 1412164
[TBL] [Abstract][Full Text] [Related]
14. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
15. Temporal expression of urokinase plasminogen activator, plasminogen activator inhibitor and gelatinase-B in chronic wound fluid switches from a chronic to acute wound profile with progression to healing.
Wysocki AB; Kusakabe AO; Chang S; Tuan TL
Wound Repair Regen; 1999; 7(3):154-65. PubMed ID: 10417751
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of urokinase-type plasminogen activator and inhibitor and gelatinase expression via 3 mitogen-activated protein kinases and PI3K pathways during the early development of osteoarthritis.
Hsieh YS; Yang SF; Lue KH; Chu SC; Li TJ; Lu KH
J Rheumatol; 2007 Apr; 34(4):785-93. PubMed ID: 17299841
[TBL] [Abstract][Full Text] [Related]
17. Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid.
van Hensbergen Y; Broxterman HJ; Hanemaaijer R; Jorna AS; van Lent NA; Verheul HM; Pinedo HM; Hoekman K
Clin Cancer Res; 2002 Dec; 8(12):3747-54. PubMed ID: 12473585
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activators in synovial fluid and plasma from patients with arthritis.
Brommer EJ; Dooijewaard G; Dijkmans BA; Breedveld FC
Ann Rheum Dis; 1992 Aug; 51(8):965-8. PubMed ID: 1417121
[TBL] [Abstract][Full Text] [Related]
19. Expression and localization of the urokinase-type plasminogen activator receptor (uPAR) in the human placenta.
Nishida Y; Hayashi Y; Imai Y; Itoh H
Kobe J Med Sci; 1998 Feb; 44(1):31-43. PubMed ID: 9846056
[TBL] [Abstract][Full Text] [Related]
20. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.
Mazzieri R; Masiero L; Zanetta L; Monea S; Onisto M; Garbisa S; Mignatti P
EMBO J; 1997 May; 16(9):2319-32. PubMed ID: 9171346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]